Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

19 Jan 2009

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 19151791
DOI: 10.1038/bmt.2008.400

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndromePMID 19151791Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selectionSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Current status of epigenetic treatment in myelodysplastic syndromesSemantic proximity Read ↗

Optimizing hypomethylating agents in myelodysplastic syndromesSemantic proximity Read ↗

Demethylating Agents in the Treatment of CancerSemantic proximity Read ↗

Decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromeSemantic proximity Read ↗

[Hypomethylating agents for the treatment of myelodysplastic syndromes].Semantic proximity Read ↗

New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic SyndromeSemantic proximity Read ↗

In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studiesSemantic proximity Read ↗

Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.